{"id":10009,"date":"2026-10-30T16:51:16","date_gmt":"2026-10-30T11:21:16","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-30\/"},"modified":"2026-10-30T16:51:18","modified_gmt":"2026-10-30T11:21:18","slug":"sunpharma-share-price-today-2026-10-30","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-30\/","title":{"rendered":"Sun Pharmaceutical Ind L Share Price Today: Why SUNPHARMA Is Rising 0.95% | 30 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: SUNPHARMA<\/strong> \u00b7 30 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b91,777.70<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+0.95%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,852.70 \/ \u20b91,770.80<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b91,761.00<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>50.96 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>30 October 2026 \u00b7 03:25 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>SUN PHARMACEUTICAL IND L (SUNPHARMA) advanced by 0.95% on Thursday, closing at \u20b91,777.70 against its previous close of \u20b91,761.00. The stock opened at \u20b91,770.90 and traded within a wide intraday range, touching a high of \u20b91,852.70 and a low of \u20b91,770.80.<\/li>\n<li>Sun Pharma announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis. The approval expands the use of the IL-23 inhibitor beyond moderate-to-severe plaque psoriasis and is supported by Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies. The medication will be administered exclusively by healthcare providers.<\/li>\n<li>Trading volume was 3.40 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Sun Pharmaceutical Ind L share price rising on 30 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">SUN PHARMACEUTICAL IND L (SUNPHARMA) advanced by 0.95% on Thursday, closing at \u20b91,777.70 against its previous close of \u20b91,761.00. The stock opened at \u20b91,770.90 and traded within a wide intraday range, touching a high of \u20b91,852.70 and a low of \u20b91,770.80.<\/p>\n<p class=\"wt-copy\">The broader market and sector backdrop provided a supportive environment for the pharmaceutical major. The benchmark Nifty index recorded a gain of 0.51%, while the Nifty Pharma sector index outperformed with a stronger move of 1.55%, reflecting broad-based buying interest across pharmaceutical equities. Over the short term, SUNPHARMA has posted a 5-day return of 1.70%, though its 20-day return stands at -2.14%, indicating recent consolidation prior to the session&#x27;s uptick.<\/p>\n<p class=\"wt-copy\">Company developments during the period included multiple corporate updates, notably the announcement of US FDA approval for ILUMYA (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis, alongside the outcome of its board meeting concerning unaudited financial results and mandatory statutory auditor rotation. While these updates provide fundamental context regarding the company&#x27;s expanding specialty portfolio and ongoing governance measures, market participants also weighed broader sector momentum during the trading session.<\/p>\n<p class=\"wt-copy\">50.96 lakh shares traded by 30 October 2026 \u00b7 03:25 PM IST. This compares with a 20-day average daily volume of 14.98 lakh shares (3.40 times). The five-day average daily volume was 12.80 lakh shares. Separately, the NSE report for 29 October 2026 showed 6.59 lakh shares delivered, representing 59.46% of that day\u2019s traded volume. The same report recorded 63,500 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Sector-led momentum and high-volume buying interest<\/strong><\/p>\n<p class=\"wt-copy\">The stock moved higher in tandem with a strong outperformance in the Nifty Pharma sector and elevated trading volumes exceeding 3.4 times its 20-day average, alongside recent ongoing product regulatory updates.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">US FDA Approval for ILUMYA in Psoriatic Arthritis<\/div>\n<div class=\"wt-card-date\">30 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Sun Pharma announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis. The approval expands the use of the IL-23 inhibitor beyond moderate-to-severe plaque psoriasis and is supported by Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies. The medication will be administered exclusively by healthcare providers.<\/p>\n<p class=\"wt-copy\">This regulatory approval broadens the commercial addressable market for Sun Pharma&#x27;s high-growth specialty dermatology and rheumatology portfolio in the United States.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Appointment of Statutory Auditors<\/div>\n<div class=\"wt-card-date\">30 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Following the conclusion of the second consecutive five-year term of existing statutory auditors S R B C &amp; CO LLP in accordance with mandatory rotation rules under the Companies Act, 2013, the board approved the appointment of Deloitte Haskins &amp; Sells Chartered Accountants LLP. The appointment is for a five-year term starting from the conclusion of the 2026-27 annual general meeting until the 2031-32 AGM, subject to shareholder approval.<\/p>\n<p class=\"wt-copy\">Ensures seamless regulatory compliance and continuity in financial oversight as per statutory governance norms.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Allotment of Non-Convertible Debentures<\/div>\n<div class=\"wt-card-date\">26 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company completed the allotment of rated, listed, unsecured, redeemable non-convertible debentures aggregating to \u20b97,816 crore on a private placement basis. This comprised Series A debentures of \u20b92,003 crore carrying an 8.05% coupon and Series B debentures of \u20b95,813 crore carrying an 8.20% coupon, after exercising a greenshoe option of \u20b9816 crore over a base issue size of \u20b97,000 crore.<\/p>\n<p class=\"wt-copy\">Demonstrates strong capital-raising capability at competitive coupon rates to support the company&#x27;s financial structure.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_26102026122925_SE_Intimation_of_allotment_of_NCDs_26_Oct_2026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Press Release<\/div>\n<div class=\"wt-card-date\">30 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 30, 2026, titled &quot;ILUMYA\u00ae (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_30102026080437_SE_Intimation_of_Press_Release_ILUMYA_PsA_Approval.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">29 September 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">&#x27;Completion and Result of Postal Ballot dated 25 August 2026&#x27;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_28092026200828_SEIntimationforVR.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">52.68%<\/div>\n<div class=\"wt-note\">54.48% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">14.36%<\/div>\n<div class=\"wt-note\">14.53% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">36.63%<\/div>\n<div class=\"wt-note\">36.71% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1738462_15102026105915_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 13.01% on 30 September 2026. This compares with 12.84% on 30 June 2026, a change of +0.17 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 51 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Icici Prudential Value Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">7.70 crore shares \u00b7 3.21%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Sbi Nifty 50 Etf<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">6.76 crore shares \u00b7 2.82%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Nippon Life India Trustee Ltd-A\/C Nippon India Etf Nifty 50 Bees<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">3.16 crore shares \u00b7 1.32%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1738462_15102026105915_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mutb400045794<\/div>\n<div class=\"wt-card-date\">24 June 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 1.54 lakh shares \u00b7 \u20b91,868.00<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mtbj400045828<\/div>\n<div class=\"wt-card-date\">24 June 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 1.54 lakh shares \u00b7 \u20b91,868.00<\/p>\n<div class=\"wt-note wt-source-note\">Public market-data page<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution and market uptake of ILUMYA following its U.S. approval for active psoriatic arthritis<\/li>\n<li>Performance trends in the global specialty medicines and US generic portfolio<\/li>\n<li>Cash volume and delivery percentage sustainability relative to the 20-day average volume baseline<\/li>\n<li>Quarterly financial performance updates and management commentary on operating margins<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-22\/\">Sun Pharmaceutical Ind L Share Price Today: Why SUNPHARMA Is Rising 0.74% | 22 October 2026 \u2014 22 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-21\/\">Sun Pharmaceutical Ind L Share Price Today: Why SUNPHARMA Is Falling 0.17% | 21 October 2026 \u2014 21 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-15\/\">Sun Pharma in Focus After CRISIL and ICRA Assign NCD Ratings | 15 October 2026 \u2014 15 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/sunpharma\/\">More Sun Pharmaceutical Ind L news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Sun Pharmaceutical Ind L company news?<\/h3>\n<p class=\"wt-copy\">Sun Pharma announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis. The approval expands the use of the IL-23 inhibitor beyond moderate-to-severe plaque psoriasis and is supported by Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies. The medication will be administered exclusively by healthcare providers.<\/p>\n<h3>How strong was Sun Pharmaceutical Ind L\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">50.96 lakh shares traded, 3.40 times the 20-day average daily volume. The price and volume data are dated 30 October 2026 \u00b7 03:25 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-30\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/sunpharma-share-price-today-2026-10-30\/\"}, \"headline\": \"Sun Pharmaceutical Ind L Share Price Today: Why SUNPHARMA Is Rising 0.95% | 30 October 2026\", \"description\": \"Sun Pharmaceutical Ind L share price rose 0.95% to \u20b91,777.70 today. See why SUNPHARMA is rising, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-30T16:51:05.278392+05:30\", \"dateModified\": \"2026-10-30T16:51:05.278392+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Sun Pharmaceutical Ind L\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"SUNPHARMA\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/sunpharma-company-news-2026-10-30.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"General Updates\",\"summary\":\"Appointment of Statutory Auditors Pursuant to Mandatory Auditor Rotation\",\"source\":\"NSE\",\"published\":\"30-Oct-2026 15:18:46\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_30102026151827_BMOutcome30102026_Conclusion.pdf\",\"disclosure_text\":\"Sun Pharmaceutical Industries Limited SUN HOUSE, Plot No. 201 B\/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 Registered Office: SPARC, Tandalja, Vadodara \u2013 390 012, Gujarat, INDIA Reaching People. Touching Lives 30 October 2026 National Stock Exchange of India Limited BSE Limited NSE Code: SUNPHARMA BSE Code: 524715 Outcome of the Board Meeting held today, i.e., 30 October 2026 - Conclusion Further to our earlier intimation made today, 30 October 2026, this is to further inform that the Board of Directors of the Company, at its meeting held today, has, inter alia, approved the following: Appointment of Statutory Auditors Pursuant to Mandatory Auditor Rotation S R B C & CO LLP, Chartered Accountants (\u201cSRBC\u201d), the existing Statutory Auditors of the Company, shall complete its second consecutive term of five years at the conclusion of the Annual General Meeting (\u201cAGM\u201d) of the Company for the financial year 2026 -27. Accordingly, SRBC shall cease to hold office as the Statutory Auditors of the Company upon completion of its tenure, in accordance with the mandatory auditor rotation requirements prescribed under Section 139(2) of the Companies Act, 2013. Based on the recommendation of the Audit Committee and subject to the approval of the shareholders of the Company, the Board has approved the appointment of Deloitte Haskins & Sells Chartered Accountants LLP (Firm Registration No. 117364W\/W100739) as the Statutory Auditors of the Company for a term of five consecutive years, commencing from the conclusion of the AGM of the Company for the financial year 2026-27 and continuing until the conclusion of the AGM of the Company for the financial year 2031- 32. The disclosures required pursuant to Regulation 30 of the Listing Regulations, read with the applicable SEBI circulars, are enclosed herewith as Annexure A. The Board Meeting commenced at 10:45 AM (IST), was adjourned for a break, subsequently resumed, and concluded at 02:55 PM (IST). For Sun Pharmaceutical Industries Limited (Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983 Sun Pharmaceutical Industries Limited SUN HOUSE, Plot No. 201 B\/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 Registered Office: SPARC, Tandalja, Vadodara \u2013 390 012, Gujarat, INDIA Reaching People. Touching Lives Annexure A Disclosure pursuant to Regulation 30 read with Para A of Part A of Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Sr. No. Particulars Details 1 Name Deloitte Haskins & Sells Chartered Accountants LLP, Firm Registration No. 117364W\/W100739 2 Reason for change viz. appointment Appointment as the Statutory Auditors of the Company consequent upon completion of the second consecutive term of the existing Statutory Auditors, S R B C & CO LLP, at the conclusion of the Annual General Meeting of the Company for the financial year 2026- 27, in accordance with Section 139(2) of the Companies Act, 2013. 3 Effective date of appointment From the conclusion of the Annual General Meeting of the Company for the financial year 2026 -27, subject to the approval of the shareholders. 4 Term of appointment Five consecutive years, commencing from the conclusion of the Annual General Meeting of the Company for the financial year 2026-27 and continuing until the conclusion of the Annual General Meeting of the Company for the financial year 2031 -32, subject to the approval of the shareholders. 5 Brief profile Deloitte Haskins & Sells Chartered Accountants LLP (Firm Registration No. 117364W\/W100739) is a firm of Chartered Accountants registered with the Institute of Chartered Accountants of India (\u201cICAI\u201d) and is part of the Deloitte network of professional services firms. The firm has extensive experience in providing audit and assurance services to large listed and multinational companies across various sectors, including pharmaceuticals, life sciences and healthcare. The firm has significant experience i n auditing leading companies in the pharmaceutical and healthcare sectors and is supported by a multidisciplinary team of audit, tax, technology and industry specialists. 6 Disclosure of relationships between directors Not applicable.\"},{\"title\":\"Outcome of Board Meeting\",\"summary\":\"Unaudited Financial Results for the quarter and half year ended 30 September 2026\",\"source\":\"NSE\",\"published\":\"30-Oct-2026 14:15:10\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_30102026141321_BMOutcomeFinancialoct26signed.pdf\",\"disclosure_text\":\"\"},{\"title\":\"Press Release\",\"summary\":\"a press release dated October 30, 2026, titled \\\"ILUMYA\u00ae (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis\\\".\",\"source\":\"NSE\",\"published\":\"30-Oct-2026 08:05:47\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_30102026080437_SE_Intimation_of_Press_Release_ILUMYA_PsA_Approval.pdf\",\"disclosure_text\":\"Sun Pharmaceutical Industries Limited Sun House, Plot No. 201 B\/1, Western Express Highway, Goregaon (E), Mumbai \u2013 400 063, Maharashtra, INDIA. Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 Registered Office: SPARC, Tandalja, Vadodara \u2013 390 012, Gujarat, INDIA. Reaching People. Touching Lives. 30 October 2026 National Stock Exchange of India Limited Scrip Symbol: SUNPHARMA BSE Limited Scrip Code: 524715 Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 \u2013 Press Release Enclosed herewith is a copy of the press release titled \u201cILUMYA\u00ae (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis\u201d which shall be released after this intimation. For Sun Pharmaceutical Industries Limited (Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983 Sun Pharmaceutical Industries, Inc. Sun House, Plot No. 201 B\/1, Western Express Highway Goregaon (E) Mumbai \u2013 400 063, Maharashtra, INDIA Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website : www.sunpharma.com Email : secretarial@sunpharma.com CIN : L24230GL1883PLC019050 FOR IMMEDIATE RELEASE ILUMYA\u00ae (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis IL-23 inhibitor approved exclusively for healthcare provider-administered treatment Expands use of ILUMYA beyond moderate-to-severe plaque psoriasis strengthening Sun Pharma\u2019s portfolio in psoriatic disease MUMBAI, INDIA and PRINCETON, NJ, (October 30, 2026) \u2013 Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, \u201cSun Pharma\u201d and includes its subsidiaries and\/or associated companies) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA \u00ae (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA). \\\"FDA approval of ILUMYA for adults with active psoriatic arthritis represents another important innovative medicine milestone for Sun Pharma and builds on the established clinical experience of ILUMYA in plaque psoriasis,\u201d said Rick Ascroft, North America CEO, Sun Pharma. \\\"As an IL-2 3 inhibitor administered exclusively by a healthcare provider, ILUMYA is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment or who may benefit from regular in-office care.\\\" Approximately 2.4 million Americans live with psoriatic arthritis, which can cause joint pain, swelling and stiffness that may lead to permanent joint damage. The approval expands the use of ILUMYA, an IL-23 inhibitor approved by the FDA in 2018 for the treatment of adults with moderate- to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. \\\"Psoriatic arthritis is a complex and chronic disease. As clinicians, we need a range of therapeutic options that allow us to individualize care based on each patient\u2019s symptoms and treatment goals. Adding an IL-23 inhibitor option that is administered by a healthcare provider gives us a new way to offer appropriate patients additional support and engagement with their healthcare team,\u201d said Philip Mease, Director of Rheumatology Research at the Swedish Medical Center and Providence St Joseph Health and Clinical Professor at the University of Washington School of Medicine, Seattle, WA. The approval is supported by Phase 3 INSPIRE-1 and INSPIRE-2 clinical studies, which evaluated the efficacy and safety of ILUMYA after only two doses at 24 weeks in adult patients with active psoriatic arthritis. 2 Reaching People. Touching Lives Safety data in the studies was consistent with the well -documented safety profile of ILUMYA. No new safety signals were identified in the INSPIRE-1 and INSPIRE-2 studies. ILUMYA may increase the risk of infection. Patients should be evaluated for tuberculo sis (TB) infection prior to initiating treatment. Most common adverse reactions are: Plaque Psoriasis (\u22651%): upper respiratory infections, injection site reactions, and diarrhea. Psoriatic Arthritis (\u22653%): upper respiratory tract infections and COVID-19. About the INSPIRE-1 and INSPIRE-2 Phase 3 Studies INSPIRE-1 and INSPIRE -2 are 52 -week, global, multicenter, randomized, double -blind, placebo- controlled Phase 3 studies evaluating the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis. Learn more about the studies at clinicaltrials.gov (INSPIRE -1 NCT04314544 and INSPIRE -2 NCT04314531). About Psoriatic Arthritis (PsA) Psoriatic arthritis (PsA) is a chronic (long-lasting or recurring) disease related to the immune system. It causes swelling, pain, and stiffness in joints and entheses (places where tendons and ligaments connect to bones).1 Psoriatic arthritis can develop at any age.2 Psoriatic arthritis can occur regardless of the severity of psoriasis (mild, moderate, or severe). Roughly 1 in 3 people living with psoriasis also have psoriatic arthritis3; typically, with psoriasis developing before psoriatic arthritis. 2 While as many as 2.4 million Americans live with psoriatic arthritis, more than 15% of people living with psoriasis may also have undiagnosed psoriatic arthritis.4 About ILUMYA\u00ae (tildrakizumab-asmn) ILUMYA (tildrakizumab-asmn) is a humanized lgG1\/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin -23 (IL-23) and inhibit its interaction with the IL -23 receptor, leading to inhibition of the release of pro -inflammatory cytokines and chemokines. ILUMYA is indicated for the treatment of adults with moderate -to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and for the treatment of adults with active psoriatic arthritis, in the United States. ILUMYA has also been approved for moderate-to-severe plaque psoriasis in India, Australia, Canada, China and Japan, and under the brand name ILUMETRI \u00ae in Europe, where it is marketed by Almirall. ILUMYA is the 1st biologic to earn the National Psoriasis Foundation (NPF) Seal of Recognition. The NPF Seal recognizes products that meet the Foundation\u2019s established review criteria and reflects Sun\u2019s continued commitment to supporting people living with psoriatic disease. INDICATION ILUMYA\u00ae is indicated for the treatment of: \u2022 moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. \u2022 active psoriatic arthritis in adult patients. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS ILUMYA is contraindicated in patients with a history of serious hypersensitivity reaction to tildrakizumab or to any of the excipients. 3 Reaching People. Touching Lives WARNINGS AND PRECAUTIONS Hypersensitivity: Cases of angioedema and urticaria occurred in ILUMYA treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy. Infections: ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing ILUMYA. Instruct patients to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection or is not responding to standard therapy, monitor the patient closely and consider discontinuation of ILUMYA until the infection resolves. Tuberculosis: Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Monitor patients for signs and sympt oms of active TB during and after ILUMYA treatment. Consider anti -TB therapy prior to initiation of ILUMYA in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Immunizations: Prior to initiating therapy with ILUMYA, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with ILUMYA. ADVERSE REACTIONS Most common adverse reactions associated with ILUMYA treatment are: \u2022 Plaque Psoriasis (\u22651%): upper respiratory infections, injection site reactions, and \u2022 diarrhea. \u2022 Psoriatic Arthritis (\u22653%): upper respiratory tract infections and COVID-19. USE IN SPECIFIC POPULATIONS Pregnancy Advise patients that there is a pregnancy exposure registry that monitors outcomes in women exposed to ILUMYA during pregnancy. Patients can enroll by calling MotherToBaby at 1-866-626-6847 or by visiting https:\/\/mothertobaby.org\/ongoing-study\/ilumya-tildrakizumab-asmn. Please see Full Prescribing Information. About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050): Sun Pharma is the world\u2019s leading specialty generics company with a presence in innovative medicines, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as globa l Emerging Markets. Sun Pharma\u2019s high -growth global Innovative Medicines portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for about 20% of company sales. The company\u2019s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. 4 Reaching People. Touching Lives Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit www.sunpharma.com and follow us on LinkedIn & X (Formerly Twitter). Disclaimer Statements in this \u201cDocument\u201d describing the Company\u2019s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be \u201cforward looking statements\u201d within the meaning of applicable securities laws and regulati ons. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments\/circumstances after the date hereof. Contacts: Sun Pharma Investors: Dr. Abhishek Sharma Tel + 91 22 4324 4324, Ext 2929 Tel Direct + 91 22 43242929 Mobile + 91 98196 86016 E-mail abhi.sharma@sunpharma.com U.S. Media: Robert Perry Mobile +1 609 921 4267 E-mail robert.perry@sunpharma.com \u00a9 2026 Sun Pharmaceutical Industries, Inc. All Rights reserved.\"}],\"recent_news\":[{\"summary\":\"Unaudited Financial Results for the quarter and half year ended 30 September 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"30-Oct-2026 14:15:10\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_30102026141321_BMOutcomeFinancialoct26signed.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"'Completion and Result of Postal Ballot dated 25 August 2026'.\",\"category\":\"Updates\",\"date\":\"28-Sep-2026 20:09:05\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_28092026200828_SEIntimationforVR.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Appointment of Statutory Auditors Pursuant to Mandatory Auditor Rotation.\",\"category\":\"General Updates\",\"date\":\"30-Oct-2026 15:18:46\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_30102026151827_BMOutcome30102026_Conclusion.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":4},{\"summary\":\"Resignation of Director of the Company.\",\"category\":\"Resignation\",\"date\":\"12-Oct-2026 20:05:00\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUNSEC_12102026200413_BMOutcome12October2026.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":3}],\"shareholding_snapshot\":{\"promoter_pct\":52.68,\"public_pct\":47.32,\"fii_pct\":14.36,\"dii_pct\":22.27,\"mf_pct\":13.01,\"institutional_pct\":36.63,\"noninst_pct\":10.7,\"mf_scheme_count\":51,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Icici Prudential Value Fund\",\"shares\":76999673,\"pct\":3.21},{\"name\":\"Sbi Nifty 50 Etf\",\"shares\":67635113,\"pct\":2.82},{\"name\":\"Nippon Life India Trustee Ltd-A\/C Nippon India Etf Nifty 50 Bees\",\"shares\":31568415,\"pct\":1.32},{\"name\":\"Hdfc Trustee Company Ltd. A\/C Hdfc Balanced Advantage Fund\",\"shares\":27282287,\"pct\":1.14}],\"period\":\"30-SEP-2026\",\"submission_date\":\"15-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1738462_15102026105915_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":54.48,\"previous_fii_pct\":14.53,\"previous_dii_pct\":22.18,\"previous_mf_pct\":12.84,\"previous_institutional_pct\":36.71,\"previous_mf_scheme_count\":49,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"bulk_block_deals\":[{\"deal_type\":\"Block\",\"date\":\"24 Jun, 2026\",\"party\":\"The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mutb400045794\",\"side\":\"Buy\",\"quantity\":\"154424\",\"price\":\"1,868\",\"source\":\"Public market-data page\",\"value\":\"\u20b928.85 Cr\"},{\"deal_type\":\"Block\",\"date\":\"24 Jun, 2026\",\"party\":\"The Mtbj Ltd. As Trst For Govrnmnt Pension Invstmnt Fund Mtbj400045828\",\"side\":\"Sell\",\"quantity\":\"154424\",\"price\":\"1,868\",\"source\":\"Public market-data page\",\"value\":\"\u20b928.85 Cr\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sun Pharmaceutical Ind L share price rose 0.95% to \u20b91,777.70 today. See why SUNPHARMA is rising, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":10008,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Sun Pharmaceutical Ind L Share Price Today: Why SUNPHARMA Is Rising 0.95% | 30 October 2026","_witty_meta_description":"Sun Pharmaceutical Ind L share price rose 0.95% to \u20b91,777.70 today. See why SUNPHARMA is rising, volume context, company developments and what to watch next.","_witty_primary_phrase":"Sun Pharmaceutical Ind L share price today","_witty_reason_label":"Sector-led momentum and high-volume buying interest","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[199],"class_list":["post-10009","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-sunpharma"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/10009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=10009"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/10009\/revisions"}],"predecessor-version":[{"id":10010,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/10009\/revisions\/10010"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/10008"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=10009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=10009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=10009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}